Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor.
about
Mifepristone (RU486) protects Purkinje cells from cell death in organotypic slice cultures of postnatal rat and mouse cerebellumAtomic structure of progesterone complexed with its receptorUbc9 is a novel modulator of the induction properties of glucocorticoid receptorsA novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in miceA complex role for the progesterone receptor in the response to vascular injuryInduction of cytotoxic T-lymphocyte antigen-2beta, a cysteine protease inhibitor in decidua: a potential regulator of embryo implantationEffect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulationCloning and uterus/oviduct-specific expression of a novel estrogen-regulated gene (ERG1)Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practiceUterine DCs are crucial for decidua formation during embryo implantation in mice.Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.Progesterone activates the principal Ca2+ channel of human sperm.Role of steroid hormone-regulated genes in implantation.Sex-specific modification of progesterone receptor expression by 17β-oestradiol in human cardiac tissues.Progesterone and RU486: opposing effects on human sperm.Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.The regulation of embryo implantation and endometrial decidualization by progesterone receptor signaling.The Role of Mifepristone in Meningiomas Management: A Systematic Review of the LiteratureA regulatory system for use in gene transfer.Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesteroneSustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine.Inhibition of the tocolytic activity of atrial natriuretic factor by progesterone and potentiation by progesterone receptor antagonist RU486 in ratsModeling hormonal and inflammatory contributions to preterm and term labor using uterine temporal transcriptomics.Regulatable gene expression systems for gene therapy applications: progress and future challenges.The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNADouble-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Nuclear progesterone receptor is mainly heat shock protein 90-free in vivoThe A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cellsRepression of the alpha-fetoprotein gene promoter by progesterone and chimeric receptors in the presence of hormones and antihormonesProgress in neuroprotective strategies for preventing epilepsy.Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat alpha 2 macroglobulin geneA mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1Intra- and inter-molecular recombination of mitochondrial DNA after in vivo induction of multiple double-strand breaks.Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers.Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial.RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.On the mechanism of action of RU486.
P2860
Q24669933-3AB01F78-6CE4-457A-84A1-9F7330866A11Q27758487-B6C66479-9EB2-449F-978C-AD9E3BBA79CAQ28216743-06440F5F-160D-4853-B956-487E0E1B7703Q28235394-14A3AF59-D7B5-4D9F-A5F2-DFCFF4A7C3BEQ28346596-F2828805-139E-4C87-89FD-2E993CD60C61Q28512227-6BDB2110-2A5B-4B7F-9EF8-8E580C56D1C6Q28538130-F91A3DA6-2E21-43EA-B7E1-971F8FE6B113Q28577370-3660B32B-D429-46E4-BF8D-9940067C77C1Q28654984-2F19412F-EF3F-44FD-B8DD-349043442BD9Q30484560-B283177E-DA09-48E9-80F6-6240FD5F6117Q33745057-B8B105A0-7BF6-4BFF-8712-92FD4BA2C409Q33923267-3F1FDDAD-A1EE-4E26-8946-E2E5D595739EQ34171208-37BEA735-CC1B-43B4-A016-284D40895469Q34397319-15AF7734-CA76-4B75-BCFC-1B0D33DB5349Q34439850-388BCD94-19D7-4390-804D-4BE57E900224Q34981900-31503903-F0C0-4EE0-BB7F-1A343251B04EQ35001895-59537CEC-7786-491A-8DB0-E25ECC95DC9DQ35667152-E804801D-F5E7-4B9D-9A95-02878A37CE57Q35683023-FD2258CF-9E0B-472E-811D-5C8D0AED23A5Q35686843-6EC31CA8-1F22-480C-B55F-6F13EF2A47F4Q35745666-3E7B498E-D5A0-477D-AFA2-742F2F13653CQ35872187-D13F761E-BF02-4BDC-BBC9-76887294B8A9Q35872275-6FB4D613-BB86-4644-B57E-87C2AFFE09F3Q36049696-D4EDBA33-8494-4C3C-AD4A-49D29A2685B0Q36157542-F72CBB29-C006-41AD-BE59-09489353ADD3Q36220795-C5911AFF-BEDB-4D7A-80C3-8381138281C7Q36298269-D028C062-3A6D-4CFE-81F1-1CC94ED3B6CAQ36346636-2E51BA36-83E5-4823-ACDE-3E6869BCF142Q36379145-F0C43270-AE45-4B89-BDB0-96F8549DFDBBQ36672641-4488AC71-0A42-49C9-9B86-8AA76AA8E80DQ36726228-4C09648F-F6CF-4E76-90CA-AADBD6C4CCA6Q36739694-4AAF63F5-C501-4768-B5B2-A31131F3CA64Q36815211-154D9E93-6C1E-44E5-82C0-E6998D9453EBQ37262115-A6B33857-7D7E-435F-972F-374EE5A534AAQ37273617-FA56EF23-DD04-450E-9D03-C4549F9277BDQ37302376-3969DAA3-A5CC-4C88-A8B3-15B6A32D9981Q37477681-78ACE22B-0026-4052-8027-1743BDF06580Q37656355-B8E24AE2-B50C-4148-9E1E-2CE5C3F19716Q37695128-C1B29001-60DA-4F91-8CC1-551E8A1478B1Q37768739-B7884257-7FA1-40FC-BF92-0991F2F46D0F
P2860
Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor.
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Contragestion and other clinic ...... iprogesterone at the receptor.
@ast
Contragestion and other clinic ...... iprogesterone at the receptor.
@en
Contragestion and other clinic ...... iprogesterone at the receptor.
@nl
type
label
Contragestion and other clinic ...... iprogesterone at the receptor.
@ast
Contragestion and other clinic ...... iprogesterone at the receptor.
@en
Contragestion and other clinic ...... iprogesterone at the receptor.
@nl
prefLabel
Contragestion and other clinic ...... iprogesterone at the receptor.
@ast
Contragestion and other clinic ...... iprogesterone at the receptor.
@en
Contragestion and other clinic ...... iprogesterone at the receptor.
@nl
P356
P1433
P1476
Contragestion and other clinic ...... iprogesterone at the receptor.
@en
P2093
Baulieu EE
P304
P356
10.1126/SCIENCE.2781282
P407
P577
1989-09-01T00:00:00Z